Ninian Lang

Has grant

Professor of Cardiology and Cardio-Oncology

University of Glasgow

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Ninian Lang is a Professor of Cardiology and Cardio-Oncology at the University of Glasgow, United Kingdom. His research focuses on cardiovascular safety in oncology, cardiotoxicity screening, and the interplay between cardiovascular and metabolic disorders. Recent articles include studies on the cardiovascular-kidney-metabolic syndrome, anthracycline-induced myocardial injury, and the incidence of chronic kidney disease in cancer patients.

Recent Grants

Grant: Close

Markers and mediators of angiogenesis inhibitor-induced vascular and myocardial toxicity: A prospective study in patients with cancer

Open Date: 2019-10-01

Close Date: 2022-03-31

Grant: Close

Cancer chemotherapeutics and the vasculature-endothelial effects of VEGF inhibitors in vivo in man

Open Date: 2016-11-01

Close Date: 2018-10-31

Grant: Close

Cancer chemotherapeutics and the vasculature- endothelial effects of VEGF inhibitors in vivo in man

Open Date: 2016-01-01

Close Date:

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (17)

David Porteous

Professor

University of Edinburgh

UNITED KINGDOM

Ninian Lang

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (16)

Cardiovascular–kidney–metabolic syndrome and mortality in a prospective UK cohort study

Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial

Cardiovascular Safety in Oncology Clinical Trials

Cardiovascular Considerations During Cancer Therapy

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology

Response by Henriksen et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction

The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes

Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort

Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies

Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort

Rationale and design of a randomised trial of intravenous iron in patients with heart failure.

Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients

Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity

Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study

Collaborators (17)

David Porteous

Robert Jones

Vishal Dey

Fozia Zahir Ahmed

Peter Ellis

Frederick Ho

Pardeep Jhund

Benjamin Elyan

Paul Welsh

Alex McConnachie

Darryl Leong

Jennifer S Lees

Elaine Rutherford

Mark Petrie

Godfrey Smith

Kaitlin Mayne

Rachel C Myles

Make your next move.